CA-QUANTA-CLOUD-TECH
26.8.2021 15:02:11 CEST | Business Wire | Press release
Quanta Cloud Technology (QCT), a leading data center hardware solution provider, today announced details around its participation at the Big 5G Event 2021 , being held onsite as well as virtually from August 30 – September 3, at the Colorado Convention Center, Denver. QCT will showcase 5G demos and solutions developed alongside ecosystem partners (Intel, Red Hat, Robin.io, Wind River, DZS) at Booth #900a for both public and private networks and share their latest insights at the event.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210826005348/en/
QCT 5G Demos, Solutions, and Partner Highlights at the Big 5G Event:
QCT 5G solutions span data center and edge, to on-premise, with two major product lines, IronInfra and OmniPOD , to address infrastructure modernization and digital transformation needs.
-
IronInfra Product Line
: QCT provides IronCloud and IronEdge solutions for telecom infrastructures.
-
IronCloud - Network Function Virtualization Infrastructure (NFVI) solutions for telecom operators. QCT IronCloud provides cloud native infrastructures for mobile network operators running 5G core, vRAN, CNFs, and CDN use cases through its ecosystem partnerships.
-
IronEdge - QCT’s edge solutions that have been approved by the Telecom Infra Project for building and supporting Open RAN in different scenarios, including Centralized RAN, Distributed RAN and MEC use cases.
-
-
OmniPOD Product Line
: End-to-end enterprise 5G network solutions that help achieve the realization of dynamic 5G applications and services.
-
OmniCore : QCT’s cloud-native, virtualized 5G core network solution that features high-availability designs to meet reliability demands and allows for the optimization of network functions.
-
OmniRAN : QCT’s 5G RAN solution consisting of BBU, FHGW, and RRU with flexible system configurations to fulfill diverse coverage and capacity needs.
-
OmniView : QCT’s Operations Administration and Management (OAM) system to manage and monitor OmniCore and OmniRAN.
-
-
Ecosystem Partner Highlights
: Developments alongside the following partners will be on-hand.
-
Intel/Red Hat : QCT builds an Open RAN CU/DU with Red Hat OpenShift, Intel FlexRAN and OpenNESS operator. It achieves automation of installation and configuration and allows easy resource management and monitoring for operators.
-
Robin.io : QCT and Robin.io developed an open and extensible cloud-native automation platform for deployment and lifecycle management of the entire 5G stack, both VNF and CNF with industry leading TCO.
-
Wind River : As a first wave partner to the Wind River Studio Hardware Ready Program, QCT completed self-validation with data center and edge servers which benefit service providers in quickly reducing OPEX while accelerating the introduction of new high-value services.
-
DZS : The QCT and DZS Converged Edge Cloud Blueprints provide simple, easy-to-deploy, jointly validated reference configurations of hardware and software for 5G network services and deployments across the Core, RAN, and Edge Access domains.
-
QCT experts will be available at Booth #900a to share their 5G journey and deployments for multiple customer POCs across industry verticals such as manufacturing, agriculture, and entertainment. Learn more at: https://go.qct.io/telco/
About Quanta Cloud Technology (QCT)
Quanta Cloud Technology (QCT) is a global data center solution provider that combines the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center design and operational challenges. QCT serves cloud service providers, telecoms and enterprises running public, hybrid and private clouds.
Product lines include hyperconverged and software-defined data center solutions as well as servers, storage, switches and integrated racks with an ecosystem of hardware components and software partners. QCT designs, manufactures, integrates and services its offerings via its own global network. The parent of QCT is Quanta Computer, Inc., a Fortune Global 500 corporation. www.QCT.io
View source version on businesswire.com: https://www.businesswire.com/news/home/20210826005348/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom